This segment encompasses the core business of PT Prodia Widyahusada Tbk, providing a wide range of clinical laboratory tests and diagnostic services. Prodia operates a vast network of branches and outlets across Indonesia, offering services such as hematology, clinical chemistry, immunology, microbiology, and molecular biology testing. Research and development activities focus on expanding the test menu, improving accuracy and efficiency, and adopting advanced technologies like automation and AI-driven analysis. The segment's impact is significant, providing crucial diagnostic information for healthcare professionals to make informed decisions, leading to improved patient outcomes. Prodia's market positioning is strong, being the largest private independent clinical laboratory in Indonesia, with a competitive advantage in its extensive network and commitment to quality. Future opportunities include expanding into new testing areas, such as genomics and personalized medicine, and leveraging digital health platforms for enhanced patient experience and service delivery. Regulatory compliance and adherence to international standards are critical aspects of this segment, ensuring the reliability and accuracy of test results. Prodia collaborates with various hospitals, clinics, and healthcare providers to offer comprehensive diagnostic solutions.

This segment focuses on leveraging digital technologies to enhance healthcare delivery and patient experience. Prodia has developed the U by Prodia app, which provides patients with access to their test results, health information, and personalized health plans. Research and development efforts are directed towards integrating AI and machine learning to improve data analysis, predictive analytics, and personalized recommendations. Technologies used include cloud computing, mobile applications, and data analytics platforms. The segment aims to improve patient engagement, provide convenient access to healthcare information, and support healthy lifestyles. Prodia's market positioning is strengthened by its digital initiatives, offering a competitive edge in terms of patient convenience and data-driven insights. Future opportunities include expanding the app's features, integrating telemedicine services, and developing AI-powered diagnostic tools. Regulatory compliance related to data privacy and security is crucial. Prodia collaborates with technology partners to develop and implement innovative digital health solutions.

This segment, operating under the brand Prodia the CRO, provides central laboratory services for clinical trials. Prodia offers a comprehensive suite of services, including sample collection, processing, analysis, and data management, supporting pharmaceutical and biotechnology companies in their drug development programs. Research and development activities focus on developing new assays, improving analytical methods, and ensuring compliance with Good Clinical Laboratory Practice (GCLP) standards. Technologies used include advanced laboratory equipment, automated systems, and data management platforms. The segment contributes to the advancement of medical research by providing reliable and accurate data for clinical trials, ultimately leading to the development of new therapies and treatments. Prodia's market positioning is enhanced by its expertise in clinical trial support, offering a competitive advantage in terms of quality and reliability. Future opportunities include expanding its service offerings, entering new therapeutic areas, and leveraging AI for data analysis. Regulatory compliance with GCP and other relevant guidelines is essential. Prodia collaborates with pharmaceutical companies, contract research organizations (CROs), and research institutions to provide comprehensive clinical trial solutions.